End Kidney Deaths Act
Summary
The End Kidney Deaths Act (HR2687) is an early-stage House bill offering a $50,000 refundable tax credit over five years for non-directed living kidney donors. With 47 cosponsors and only a referral to two committees, the bill is procedurally distant from passage. The structural tailwind for transplant-related clinical lab volumes at Labcorp ($LH) and Quest Diagnostics ($DGX) is real but de minimis relative to their total operations. No market-moving impact at this legislative stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2687 is an early-stage bill with 47 cosponsors, referred to two committees — significant legislative path remains before any market impact
- 2.The $50,000 refundable tax credit is a tax expenditure, not direct spending — no procurement or contracting mechanism exists
- 3.Labcorp and Quest Diagnostics would see de minimis revenue lift from any increase in living donor transplants; impact is below materiality thresholds
- 4.Real market data for $LH and $DGX shows no abnormal price movement linked to this legislation
Market Implications
There is no actionable market signal from HR2687 at this stage. Both (current $262.73) and (current $195.17) are trading within their 52-week ranges with normal volatility. The bill's potential to drive transplant testing volumes is structurally real but financially immaterial — annual revenue impact would be measured in single-digit millions against multi-billion dollar revenue bases. Investors should not trade on this bill. The only scenario that changes this assessment is committee markup with amendments, introduction of a Senate companion bill, or a Congressional Budget Office score showing meaningful projected transplant volume increases.
Full Analysis
The End Kidney Deaths Act (HR2687) was introduced in the House on April 7, 2025 by Rep. Malliotakis (R-NY) and referred to the Ways and Means and Energy and Commerce Committees. The bill provides a $50,000 refundable tax credit ($10,000/year for five years) for individuals who make non-directed living kidney donations. This is an early-stage authorization bill — it does not appropriate any funds, only creates a tax credit mechanism through the tax code.
The money trail is a tax expenditure: the federal government forgoes up to $50,000 per donor over five years. There is no direct contracting or procurement. The incentive is designed to increase the supply of living kidney donors, which would modestly increase the number of kidney transplants performed annually. Currently about 6,000 living donor kidney transplants occur per year in the US; a 10% increase would add ~600 procedures.
Structural winners are Labcorp and Quest Diagnostics, which perform HLA typing, crossmatching, viral screening, and post-transplant monitoring for kidney transplant programs. However, transplant-related testing represents a tiny fraction of each company's revenue. Labcorp's total 2025 revenue is approximately $14 billion; Quest's is about $10 billion. Even a generous estimate of incremental transplant testing revenue ($2-3 million annually) is immaterial to either company's bottom line.
Real market data shows at $262.73 (down 1.53% over 30 days) and at $195.17 (down 0.41% over 30 days). Both stocks are within their 52-week ranges, showing no abnormal price action linked to this bill. The 7-day changes (-0.41% for , -0.56% for ) are consistent with normal trading patterns.
Legislative timeline: The bill has 47 cosponsors from both parties and is in two committees. It requires committee markup, House floor vote, Senate introduction and passage (no companion bill exists yet), and presidential signature. Given that this is the 119th Congress (2025-2027), the earliest possible passage would be late 2026. With no companion bill and the current committee referral status, the bill is unlikely to advance significantly this session.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
HUMAN SERVICES, NEW JERSEY DEPARTMENT OF: $16.9B Department of Health and Human Services Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
GOVERNOR'S AUTHORIZED REPRESENTATIVE: $1.8B Department of Homeland Security Grant
DEPARTMENT OF SOCIAL SERVICES MISSO: $15.1B Department of Health and Human Services Grant
MINNESOTA DEPARTMENT OF HUMAN SERVICES: $14.1B Department of Health and Human Services Grant
GEORGIA EMERGENCY MANAGEMENT AND HOMELAND SECURITY AGENCY: $1.6B Department of Homeland Security Grant
MARYLAND DEPARTMENT OF HEALTH: $11.5B Department of Health and Human Services Grant
OKLAHOMA HEALTH CARE AUTHORITY: $8.2B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →